Drug management in chronic rhinosinusitis: identification of the needs by Watelet, Jean-Baptiste HPJ et al.
Therapeutics and Clinical Risk Management 2007: 3(1) 47–57
© 2007 Dove Medical Press Limited. All rights reserved
47
REVIEW
Drug management in chronic rhinosinusitis:
identification of the needs
Jean-Baptiste HPJ Watelet1
Philippe H Eloy2
Paul B van Cauwenberge1
1Department of Otorhinolaryngology,
University of Ghent, Ghent, Belgium;
2Department of Otorhinolaryngology,
CHU Mont-Godinne, Université
Catholique de Louvain, Yvoir, Belgium
Correspondence: JB Watelet
Department of Otorhinolaryngology,
University of Ghent, UZ Gent 1P1,
De Pintelaan, 185, B-9000 Gent, Belgium
Tel +32 9240 2332
Fax +32 9240 4993
Email jeanbaptiste.watelet@ugent.be
Abstract: Chronic rhinosinusitis (CRS) is a group of multifactorial diseases characterized by
inflammation of the mucosa of the nose and paranasal sinuses with a history of at least 12 weeks
of persistent symptoms despite maximal medical therapy. The precise role played by infection
and immunoglobin E (IgE)-mediated hypersensitivity remains unclear. Diagnosis of CRS is
based upon medical history, nasal endoscopy and computed tomography scan of the sinuses.
The CRS with polyps visible in the middle meatus must be distinguished from the CRS without
polyps. Based on the current knowledge about the pathogenesis of CRS, it is admitted that an
optimal medical treatment must consider all favorizing factors and control efficaciously the
inflammation process. In case of failure of medical treatment, endoscopic sinus surgery should
be proposed. However, some well-validated data and scientific evidences are missing, even for
the most frequently used medications. After a review of the actual definitions and classifications,
a short description of the current knowledge about pathogenesis of CRS is provided in order to
justify the actual therapeutic rationales and identify the needs for an effective treatment of CRS.
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Introduction
Rhinosinusitis is one of the most common healthcare complaints in US and Europe
(Van Cauwenberge and Watelet 2000). The burden of affected individuals in terms of
decreased productivity, absenteeism from the workplace, and diminished quality of life,
when added to the costs of care and growing public health menace of antibiotic-resistant
bacteria, makes rhinosinusitis a serious disease (Winstead 2003). Affecting nearly 16%
of the adult population annually (Anand 2004), rhinosinusitis induces subsequent direct
and indirect costs: in 1996, in US, the annual medical expenditure for sinusitis was
US$3.39 billion and the indirect costs due to lost work were nearly US$3.8 billion (Ray
et al 1999). Because of this significant impact on public health and socio-economy,
rhinosinusitis warrants precise diagnosis and effective therapy.
Several position papers and guidelines on rhinosinusitis have been recently
published by experts or scientific societies (Grevers and Klemens 2002; Anon et al
2004; Brink et al 2004; Ressel 2004; Varonen and Saino 2004; Blomgren et al 2005;
Klossek and Federspil 2005; Poole and Portugal 2005; Wright and Frenkiel 2005). In
December 2004, The American Academy of Allergy, Asthma and Immunology, The
American Academy of Otolaryngic Allergy, The American Academy of
Otorhinolaryngology-Head and Neck Surgery, The American College of Allergy, Asthma
and Immunology, and The American Rhinologic Society developed consensus
definitions for rhinosinusitis and strategies for patient care (Meltzer et al 2004a, 2004b).
This expert panel composed of allergists, otorhinolaryngologists, microbiologists,
and radiologists outlined criteria for research dealing with pharmacologic and surgical
intervention in rhinosinusitis. More recently, the European Academy of AllergologyTherapeutics and Clinical Risk Management 2007: 3(1) 48
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and Clinical Immunology (EAACI), in close collaboration with
the European Rhinologic Society, updated the knowledge of
rhinosinusitis and nasal polyposis and provided evidence-
based medicine documents (Fokkens 2005) on diagnosis
methods and available treatment for rhinosinusitis (Fokkens
et al 2005a, 2005b).
From these reviews and consensus, it appears that the
recent innovations in endoscopy, imaging and biology have
considerably improved our understanding of sinus
pathogenesis. However, from a general practitioner or Ear,
Nose, and Throat (ENT) specialist point of view, the diagnosis
of rhinosinusitis remains mainly clinical and the treatment is
usually empiric, even if, especially when considering chronic
rhinosinusitis (CRS), it is now admitted that rhinosinusitis is
not simply an infectious disease but a complex and
multifactorial disorder. Finally, the development of new
medications has significantly increased the therapeutic
possibilities for the drug management of CRS.
Interestingly, when considering the literature on the drug
management of CRS, it appears that many questions remain
unanswered and scientific evidence is dramatically missing.
In this paper, after a short description of the clinical and
biological background of CRS, the major needs for research
in drug management of CRS are identified.
Definitions
Different types of definitions can be found in the literature
on chronic rhinosinusitis. Some of them are dedicated to
clinicians, general practitioners, or specialists, while the
others are specifically designed for epidemiological surveys
or research.
In 2003, a task force convened by the Sinus and Allergy
Health Partnership defined chronic rhinosinusitis as a group
of disorders characterized by inflammation of the mucosa of
the nose and paranasal sinuses of at least 12 weeks duration
(Benninger et al 2003). As recently claimed by the American
Position Paper (Meltzer et al 2004a), objective documentation
is required by means of direct visualization of the middle
meatus through anterior rhinoscopy, nasal endoscopy to
assert the accurate diagnosis of CRS. For the American experts,
although rhinosinusitis can be diagnosed in the majority of
patients by using only clinical judgment, patients with
recurrent or complicated sinus disease might require imaging
studies. Imaging is also considered as absolute requirement
for the research on CRS.
In the EAACI position paper, the definition of CRS relies
on positive computed tomography (CT) changes even in the
definition designed for daily practice (Table 1). For research
purposes, attention must be paid on the presence or not of
nasal polyps in the middle meatus for differentiating chronic
rhinosinusitis without polyps (CRS) from chronic
rhinosinusitis with nasal polyps (CRSwNP).
Clinical presentation, assessment
and classifications
A clinical diagnosis is based on history and evaluation with
endoscopy and computerized tomographic scanning.
Patients with CRS and patients suffering from CRSwNP
both complain of nasal obstruction, discharge, facial
pressure or pain, and smell disorders. These symptoms are
present for a period of more than 3 months. The nature,
severity, or duration of clinical complaints does not allow
the clinician to distinguish CRS from CRSwNP. Anterior
rhinoscopy is the basic tool of the physical examination
that relates to determining the existence of pathology in
the sinonasal passages. However, examination of the nasal
passages beyond the anterior portion can be limited.
Presently, the current subjective diagnosis paradigm for
chronic rhinosinusitis is most cost-effective but least
accurate.
Endoscopy and/or CT screening were much better at
appropriate diagnosis and targeted therapy but charges
indicated a much higher cost (Stankiewitcz and Chow 2003).
The nasal endoscopy, with use of a flexible fiberoptic
endoscopes or rigid telescope, detects diseases missed on
routine history or clinical examination and helps identify
erythema, polyps or polypoid swelling, edema, crusting and
mucopus. Finally, besides its essential function in
preoperative evaluation, endoscopy could also have multiple
uses in both the medical and surgical management of chronic
rhinosinusitis: eg, in guiding microbiological sampling or
biopsies (Kuhn 2004).
Although rhinosinusitis can be diagnosed in the majority
of patients by using only the history and physical
examination (including endoscopy), patients with persistent
sinus disease, with recurrent or complicated sinus disease
often require imaging studies. Several rhinosinusitis staging
systems utilizing CT techniques are available (Zinreich
2004). Patients suffering from CRSwNP have higher CT scores
at presentation and more severe symptoms (Deal and
Kountakis 2004).
Based on these evidences, the experts of the American
position paper agreed with a consensus classification of CRS
for both clinical use and research purposes. CRS patientsTherapeutics and Clinical Risk Management 2007: 3(1) 49
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Figure 1 Clinical features: (A) CRS: CT scanner sinuses. Bilateral opacity of maxillary and ethmoid sinuses; (B) CRSwNP: endoscopic view (30° Hopkins telescope, left
nasal cavity). Nasal polyps in middle meatus.
Figure 2 Flowchart for diagnosis and management of CRS and CRSwNP: view for General Practitioner and for Ear, Nose, and Throat specialist (Fokkens et al 2005a).
should be categorized in function of the presence of
endoscopically visible nasal polyps in middle meatus, of
associated eosinophilic or other inflammatory features
(Meltzer et al 2004a). Finally, the severity of symptoms is staged
into mild, moderate, or severe in function of the trouble induced
by CRS symptoms using a visual analogue scale or, when
considering CRSwNP, in case of comorbidities (Fokkens et al
2005a).
Pathogenesis
The etiology of CRS and CRSwNP is multifactorial and
comprises a vicious circle of pathophysiological, anatomical
and constitutive factors. Various causative agents play a role
in rhinosinusitis including microorganisms, allergic and non
allergic immunologic inflammation and non infectious, non
immunologic causes. The Table 2 summarizes the main factors
considered as associated to or inducers of the CRSTherapeutics and Clinical Risk Management 2007: 3(1) 50
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inflammatory reaction and identifies some potential targets
for drug management.
The possible indirect contamination of sinus cavities
during common cold has been evoked. During a common
cold, nasal fluid containing viruses, bacteria and inflammatory
mediators is blown into the sinuses where they produce
mucosal edema, cellular infiltration, mucus thickening and
infection (Puhakka et al 1998; Alho 2003, 2004).
There are more documented evidences about allergic and
immunologic factors associated to the development of
rhinosinusitis. Perennial allergic rhinitis has a statistically
significant association with chronic and recurrent acute
rhinosinusitis (Gutman et al 2004).
On a biological point of view, recent evidences suggest
that, despite clinical similarities, CRS and CRSwNP are
distinct entities with separate inflammatory pathways and
cytokine profiles (Gillespie and Osguthorpe 2004).
Examining the histology of middle turbinate tissues from
patients with polypoid versus nonpolypoid disease might
allow for distinction between these 2 entities. CRS is
histopathologically characterized by a predominant
neutrophilic inflammation with a lesser contribution of
eosinophils. Furthermore, CRS is characterized by basement
membrane thickening, goblet cell hyperplasia, and prominent
subepithelial fibrosis. On the other hand, CRSwNP
is characterized by eosinophilic inflammation. Besides
an active eosinophilic recruitment and activation,
histomorphologic characterization of CRSwNP also reveals
frequent epithelial damage, variable stages of thickened
basement membrane, and mostly edematous to sometimes
fibrotic stromal tissue, with a reduced number of vessels and
glands. The particular inflammatory reaction of CRSwNP
could be partially explained by the following processes: late-
phase allergic inflammation in response to airborne allergens;
dysregulation of sinus epithelium with overproduction of
chemokines; T-cell activation in response to fungal antigens
(hyphae); or in response to bacterial superantigens. It is clearly
demonstrated that interleukin (IL)-5 and eotaxin could play
a pivotal role in the latter process by recruiting and activating
eosinophils. A discordance between systemic allergic
phenotype and local inflammatory mechanisms leading to
eosinophilic inflammation in nasal polyps was suggested
because neither total immunoglobin E (IgE) concentrations
nor eosinophilic cationic protein (ECP), IL-4, or IL-5
concentrations were found different in atopic versus
nonatopic subjects. A role has been proposed for IgE specific
for staphylococcal-derived superantigens in the pathogenesis
of CRS associated with nasal polyps. Finally, different
patterns in leukotriene production have been demonstrated
in CRS with and without polyps (Perez-Novo et al 2005).
Table 1 Clinical definition of rhinosinusitis/nasal polyps following the EP3OS document (Fokkens et al 2005b)
Definition Symptoms Other
and either Endoscopic signs:
- polyps
- mucopurulent
discharge from middle
meatus
Inflammation of the - blockage/congestion - oedema/mucosal
nose and the - discharge: anterior/post
paranasal sinuses nasal drip obstruction primarily in
characterized by two - facial pain/pressure middle meatus
or more symptoms: - reduction or loss of smell
and/or CT changes:
- mucosal changes
 within ostiomeatal
complex and/or sinuses
Severity:
- use of visual analogue scale score (0–10 cm)
- 0: not troublesome
- 10: most troublesome imaginable
Duration:
- < 12 weeks with complete resolution: acute/intermittent
- > 12 weeks with no complete resolution: chronic/persistentTherapeutics and Clinical Risk Management 2007: 3(1) 51
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Other non inflammatory parameters have been suspected
to induce or at least participate in the CRS evolution.
Dysfunction of autonomic nerve pathways, other non-
inflammatory properties of leukotrienes,
hyperresponsiveness or local irritation caused by
gastroesophageal reflux were demonstrated in selected
subsets of patients with rhinosinusitis and could participate
in the pathogenesis of CRS. Defects in mucociliary clearance
(eg, primary ciliary dyskinesia, cystic fibrosis, Young’s
syndrome, etc) and antibody deficiency syndromes
predispose to rhinosinusitis like aspirin-associated respiratory
diseases. Finally, as in the pathogenesis of allergy or asthma,
the role of indoor or outdoor pollution and tobacco smoke
has been suggested.
Current treatments
and guidelines
Treatment aims to reduce the mucosal inflammation and
swelling, to control infection, and restore aeration of the nasal
and sinus mucosa.
A modern treatment of CRS should respect several
principles.
First of all, it should consider the patient in totality: from
etiology, when possible, till clinical features. When
considering patients with CRS, comorbidities such as asthma
must not be underestimated especially during the decision
process for therapy.
A modern treatment for CRS should also reflect the new
findings in pathogenesis. Even if the actual debate on initial
causes or polyp formation is still active, the clinicians should
try to categorize their patients in function of the presence or
not of nasal polyps at the middle meatus. The clinical
evolution seems to be significantly different between the
groups. However, the nature and severity of inflammation or
irreversible damages are usually difficult to be assessed in
daily practice. At this regard, some clinical or biological
criteria can be suggestive: eg, hypereosinophilic syndrome
or hyper-IgE syndromes are regularly associated to
CRSwNP.
A modern treatment of CRS should profit from the most
recent pharmacological improvements. New classes of
medications can be identified on the basis of pathogenesis
knowledge. For example, the recent developments of
specific drugs acting against cytokines or growth factors
involved in the CRS course are illustrative of this evolution,
like the inhibitors of the leukotriene cascade or
immunomodulatory drugs. The different options for
manipulating the T-cells responsible of the inflammatory
reaction seem to be promising for patients suffering from
allergies or asthma and probably will be applied soon in
CRS treatments. Because of the multiplicity of interactions
between targets, a subtle combination of molecules is
probably needed and should increase the respective efficacy
of the medical treatment of CRS. Finally, thanks to recent
advances in pharmacokinetics, new ways of drug
administration being developed.
A modern treatment of CRS should adapt its schemes to
evidence-based medicine. Unfortunately, basic evidence on
drug efficacy in CRS is still missing. As mentioned by the
EP³OS expert panel (Fokkens 2005), validated trials are
lacking even for the most prescribed medications against
CRS such as antibiotics.
Finally, as all treatment for chronic diseases, an adequate
management of CRS should need a regular evaluation of
efficacy and revision. A multidisciplinary approach and
follow-up is mandatory as diseases such as cystic fibrosis
can generate sinus diseases.
Medical treatments
Extensive reviews have been recently published on the
medical management of chronic rhinosinusitis (Scadding
2004). Different classes of medications could be proposed
to patients with CRS (Aukema and Fokkens 2004).
Treatment of the causative agent
When correctly identified and available, the first step of the
treatment of CRS should be to manage the underlying cause.
For example, oral antihistamines should be prescribed in
patients with a proven allergy, but there is little evidence of
their efficacy in CRS even with nasal polyps. Another
example: proton pump inhibitors are the modality of choice
for the treatment of gastroesophageal reflux associated with
CRS, but the efficacy on sinus symptoms is limited (Ulualp,
Toohill, et al 1999; DiBiaise et al 2002).
Considering infection as a causative factor for the
development of CRS, systemic antibiotics are often
administered to patients with chronic sinusitis and underlying
bacterial infection. Oral broad spectrum antibiotics are
indicated for the treatment of acute bacterial exacerbation of
CRS. Amoxicillin and amoxicillin plus clavulanic acid
remain the first choice (Dinis et al 2000; Passali et al 2001).
Prolonged use of low-dose macrolides has been proposed
(Suzuki and Ikeda 2002; Gillespie and Osguthorpe 2004;
Siddiqui 2004; Wallwork and Coman 2004). The use ofTherapeutics and Clinical Risk Management 2007: 3(1) 53
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fluoroquinolones for upper respiratory tract infections has
been evoked as acting against Gram-negative bacteria,
Staphylococcus aureus, and Streptococcus pneumoniae.
Reports exploring the efficacy of new generation of
fluoroquinolone are available: levofloxacin (Hurst et al 2002;
Gillespie and Osguthorpe 2004) and mostly moxifloxacin
(Faich et al 2004). Finally, since Ponikau and colleagues
(1999) suggested that chronic rhinosinusitis and nasal polyps
have a fungal origin, there are now publications exploring
the possible efficacy of nasal lavages with antimycotics in
chronic rhinosinusitis (Ponikau et al 2002, 2005; Fergusson
2003).
Finally, environmental factors or allergic factors may
predispose individuals to CRS. In these patients, the following
preventive measures may be helpful: reduced exposure to
pollution, cigarette smoke, dust, moulds, and other environmental
chemical irritants.
Treatment of sinus inflammation
and subsequent damages
It was suggested that antibiotics and nasal steroids are the
basic treatment for CRS (Dolor et al 2001), whereas
combination of systemic and local steroids are the foundation
of CRSwNP (Gillespie and Osguthorpe 2004). Even if the
relative importance of antibiotics is still actively debated in
chronic mucopurulent rhinosinusitis (Sykes et al 1986), it is
now well accepted that the background inflammatory reaction
must be actively treated in CRS. Several studies about the
topical glucocorticosteroids prescribed in CRS are available.
They are considered as effective treatment in CRS with or
without polyps as demonstrated by several randomized
double-blind studies (Keith et al 2000; Parikh et al 2001;
Giger et al 2003; Dijkstra et al 2004; Lund et al 2004; Patel et
al 2004; Aukema et al 2005). However, these studies
demonstrate only minor improvement in non-operated
patients. This was partially explained by a lack of penetration
into the sinuses by topically applied drugs. In CRS with
eosinophilic inflammation, topical steroids are routinely
prescribed for at least 3 to 6 months with few reports on
systemic or local adverse events.
Other medical treatments have been discussed in the
literature. The intranasal saline was shown to decrease nasal
symptoms in chronic sinusitis (Taccariello et al 1999). It
improves quality of life in patients with CRS and reduces the
amount of secretions, postnasal drip, and the load of mediators
in the secretions. Cromoglycate (Lomusol, Aventis Pharma,
Paris, France) was not considered in the treatment of CRS.
Although there is little supporting evidence, nasal
decongestants are commonly prescribed in patients suffering
from CRS. A study using magnetic resonance imaging showed
only a brief and transient decongestant effect on inferior and
middle turbinates with no shrinking of maxillary and ethmoid
linings after use of xylometazoline (Benammar-Englmaier
et al 1990). Capsaicin and ipratropium bromide, indicated in
different types of rhinitis, were never tried in clinical studies
in patients with CRS.
Finally, there are only few data available on clinical trials
with antileukotrienes in CRS (Ulualp, Sterman, et al 1999;
Wilson et al 2001). No published clinical studies using anti-
cytokines, anti-growth factors or anti-metalloproteinases
agents have been reported for the treatment of CRS (Amrol
and Murray 2005; Bachert et al 2005). Finally, there exists
no report on immunomodulating agents in CRS.
Surgical treatment
Reviews on the surgical management of chronic rhinosinusitis
have been recently published (Strong and Sender 2003;
Witterick et al 2004).
Recent advances in endoscopic technology and a better
understanding of the importance of the ostiomeatal complex
in the pathophysiology of sinusitis have led to the
development of functional endoscopic sinus surgery (FESS).
FESS aims to remove pathologic mucosa inside the paranasal
cavities of disease, to restore an adequate aeration and
drainage of the sinuses. This surgical procedure is a common
adjunct to medical therapy in the management of chronic
rhinosinusitis and nasal polyposis. If symptoms persist after
failure or partial or temporary relief after medical treatment,
surgery should be proposed.
Postoperatively the majority of the patients experience
significant reduction of headache, nasal obstruction, post
nasal drip and are improved in Quality of Life scores (Damm
et al 2002; Chiu et al 2004; Iro et al 2004). In patients with
asthma, FESS improves peak expiratory flow and reduces the
use of inhaled and systemic glucocorticosteroids (Dhong
et al 2001; Palmer et al 2001; Dunlop et al 1999; Goldstein
et al 1999; Ikeda et al 1999; Senior et al 1999). The importance
of postoperative use of medications is still poorly
demonstrated (Lavigne et al 2002).
Identification of the needs
From the EAACI position paper and state-of-the-art reports it
appears that only a few studies have respected the highest
standards for clinical trials and that, as a consequence, someTherapeutics and Clinical Risk Management 2007: 3(1) 54
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essential information about the efficacy and safety of drug
management in CRS are missing.
Need of complementary data on CRS
pathogenesis
As suggested earlier in the Pathogenesis section, some
fundamental debates are inducing doubts and misunder-
standings in the clinician community. More evidence about
the initialization and clinical course of CRS is clearly
required. Models developed in fundamental research on
microbiology and inflammation in CRS could find ways of
combining the medications available and define new targets
for therapy to prevent the development of sinus inflammatory
disease and reduce the episodes of recurrences. Further
research on clinical and biological categorization of patients
could lead to new subclassifications and more adapted
treatments for CRS patients.
Need to address the patient in his/her
totality
Based on a better understanding of the basic physiopathology
and a more systematic and complete description of clinical
comorbidities, new concepts for preoperative evaluation and
postoperative monitoring of CRS patients could be
developed. For example, the assessment of comorbidities
should merit evidence-based guidelines. Finally, the quality
of life of CRS patients has only partially been explored (Smith
2004). Complementary data are needed and schemes for
regular evaluation of quality of life or sleep disorders should
be designed for CRS.
Need of evidence in the currently-
proposed medical treatment
Using Shekelle’s categories of evidence summarized in Table 3
(Shekelle et al 1999), only topical steroids and antimycotics
were tested using double-blind placebo controlled studies
or meta-analyses (Table 4). Antibiotics, local or topical for
short- or long-term treatment, nasal douching, mucolytics,
and proton pump inhibitors have a category III of evidence,
based only on evidence from non-experimental descriptive
studies. Data are not available for decongestants (oral,
topical), oral antimycotics or antihistamines, immunotherapy
and phytotherapy.
Randomized prospective long-term studies for efficacy
of antibiotics (systemic or topical) are urgently needed in
CRS. Because of its costs and potential risks of microbial
resistance, the use of antibiotics must be evaluated using the
best-designed protocols. Regarding decongestants, one of
the most frequent drugs used in upper airway inflammation,
their long-term positive or negative effects on the CRS
course should merit more attention from researchers. Finally,
the promising anti-inflammatory medications already
used in several rhinitis trials, were never applied in CRS
patients.
Need of evidence in the current view
of surgical treatment
As with most surgical procedures, there is a paucity of
randomized, controlled clinical trials examining the use of
FESS in the management of CRS and CRSwNP (Chiu et al
Table 3 Sekelle’s evidence scale. Reproduced with permission from Shekelle PG, Woolf SH, Eccles M, et al. 1999. Clinical
guidelines: developing guidelines. BMJ, 318:593-6. Copyright © 1999. British Medical Journal.
Category of evidence Subcategory Evidence obtained from:
I a Meta-analysis of randomized controlled trials
b At least one randomized controlled trials
II a At least one controlled study without randomization
b At least one other type of quasi-experimental study
III Nonexperimental descriptive studies:
- or comparative studies
- or correlation studies
- or case-control studies
IV - or expert committee reports
- or opinions or clinical experience of
 respected authorities,
 - or bothTherapeutics and Clinical Risk Management 2007: 3(1) 55
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2004). There is also an urgent need to compare the functional
effects of medical with surgical treatment of CRS and CRSwNP.
Although one recent report has been published about the
integration of medical and surgical treatment (Ragab et al
2004), the way how to implement them in daily practice
must be clarified. Step-wise approaches summarized in
guidelines for general practitioners and ENT-specialists
should be developed.
Furthermore, it is absolutely mandatory to design surveys
to determine the precise nature, duration, and dosage of
medication to be used before, during, and after the surgical
procedure. Nowadays, the prescription of post-operative drugs
remains purely arbitrary.
Conclusions
Because of its complex pathogenesis of CRS and the
uncertainties regarding the precise role played by the
involved processes, the current management of CRS remains
empirical or based on expert opinions. Some requirements
are clearly identified such as the need of complementary
evidence on CRS pathogenesis, the need of addressing the
patient in his totality, the need of evidence in the currently
proposed medical treatment or in the current view of surgical
management. The challenge of further research in this field
will be to combine a complete fulfilling of the missing
evidence and the active development of new therapeutic
strategies.
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